Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management.

Current problems in cardiology - 1 Jun 2023

Eljilany Islam, Elewa Hazem, Al-Badriyeh Daoud

Abstract excerpt

Warfarin is commonly used in thromboembolic conditions. Warfarin interruption represents a significant challenge in pre-operative warfarin management as it is associated with major consequences. Genetics polymorphism demonstrated to be a significant predictor of the required days of warfarin interruption. This study sought to assess the economic benefit of implementing a pharmacogenetic-guided approach in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cost-Benefit Analysis
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Thromboembolism

Share to Warfarin

Source

Identifiers

PMID: 35114296
DOI: 10.1016/j.cpcardiol.2022.101128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management.PMID 35114296Read ↗

The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.Semantic proximity Read ↗

Pharmacoeconomic evaluation of warfarin pharmacogenomics.Semantic proximity Read ↗

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.Semantic proximity Read ↗

Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.Semantic proximity Read ↗

Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.Semantic proximity Read ↗

A randomized trial of genotype-guided dosing of warfarin.Semantic proximity Read ↗

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.Semantic proximity Read ↗

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.Semantic proximity Read ↗

Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.Semantic proximity Read ↗

A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.